These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 5828888)

  • 41. Optimum age for measles immunisation: study of pre- and post-immunization level of HI antibody titres.
    Bhatnagar SK; Mohan M; Kumar P; Balaya S; Prabhakar AK; Bhargava SK
    Indian Pediatr; 1981 Sep; 18(9):625-9. PubMed ID: 6797943
    [No Abstract]   [Full Text] [Related]  

  • 42. Appearance and persistence of antibodies against different virus components after regular measles infections.
    Norrby E; Gollmar Y
    Infect Immun; 1972 Sep; 6(3):240-7. PubMed ID: 4118046
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Persistence of measles antibody in the absence of circulating natural virus five years after immunization of an isolated virgin population with Edmonston B vaccine.
    Brown P; Gajdusek DC; Tsai T
    Am J Epidemiol; 1969 Dec; 90(6):514-8. PubMed ID: 5362859
    [No Abstract]   [Full Text] [Related]  

  • 44. Evaluation of measles-rubella vaccination for mothers in early puerperal phase.
    Hisano M; Kato T; Inoue E; Sago H; Yamaguchi K
    Vaccine; 2016 Feb; 34(9):1208-14. PubMed ID: 26801065
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Reactions of immunoglobulins and specific antibodies in vaccinated and nonvaccinated children with measles (author's transl].
    Wiedermannová D; Wiedermann D; Bozdĕchová M; Pejćochová J
    Cas Lek Cesk; 1977 Feb; 116(7):205-9. PubMed ID: 851980
    [No Abstract]   [Full Text] [Related]  

  • 46. Sensitizing versus immunizing properties of inactivated measles vaccine.
    Wilson S; Aprile MA
    Prog Immunobiol Stand; 1970; 4():657-60. PubMed ID: 4991597
    [No Abstract]   [Full Text] [Related]  

  • 47. Measles Virus Hemagglutinin epitopes immunogenic in natural infection and vaccination are targeted by broad or genotype-specific neutralizing monoclonal antibodies.
    Muñoz-Alía MA; Casasnovas JM; Celma ML; Carabaña J; Liton PB; Fernandez-Muñoz R
    Virus Res; 2017 May; 236():30-43. PubMed ID: 28465158
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Measles antibodies in the cerebrospinal fluid of patients with multiple sclerosis.
    Brown P; Cathala F; Gajdusek DC; Gibbs CJ
    Proc Soc Exp Biol Med; 1971 Jul; 137(3):956-61. PubMed ID: 4934707
    [No Abstract]   [Full Text] [Related]  

  • 49. [Comparative results of anti-measles serological immunity after the disease and after vaccination].
    Topciu V; Moldovan E; Csaky N; Băcilă E
    Arch Roum Pathol Exp Microbiol; 1970 Dec; 29(4):671-5. PubMed ID: 5521121
    [No Abstract]   [Full Text] [Related]  

  • 50. Measles immune-status surveys in Manitoba.
    Sekla L; Stackiw W; Drewniak M
    Can J Public Health; 1979; 70(6):415-7. PubMed ID: 534989
    [No Abstract]   [Full Text] [Related]  

  • 51. [A study on measles immune status by ELISA].
    Li GQ
    Zhonghua Liu Xing Bing Xue Za Zhi; 1989 Apr; 10(2):105-8. PubMed ID: 2736614
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Vaccination against measles in the Canadian Arctic.
    Furesz J; Habgood M
    JAMA; 1966 Jan; 195(5):342-4. PubMed ID: 5951890
    [No Abstract]   [Full Text] [Related]  

  • 53. An epizootic of measles in captive silvered leaf-monkeys (Presbytis cristatus) in Malaysia.
    Montrey RD; Huxsoll DL; Hildebrandt PK; Booth BW; Arimbalam S
    Lab Anim Sci; 1980 Aug; 30(4 Pt 1):694-7. PubMed ID: 7421117
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunity against measles and rubella in Massachusetts schoolchildren.
    Orenstein WA; Herrmann K; Albrecht P; Bernier R; Holmgreen P; Bart KJ; Hinman AR
    Dev Biol Stand; 1986; 65():75-83. PubMed ID: 3556779
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison between haemagglutination inhibition test and enzyme immunoassay for evaluation of measles immune status and seroconversion to measles vaccine.
    Gebreselassie L; Melamed MD
    Ethiop Med J; 1983 Jul; 21(3):139-42. PubMed ID: 6349985
    [No Abstract]   [Full Text] [Related]  

  • 56. Booster vaccination with further live attenuated measles vaccine.
    Bass JW; Halstead SB; Fischer GW; Podgore JK; Pearl WR; Schydlower M; Wiebe RA; Ching FM
    JAMA; 1976 Jan; 235(1):31-4. PubMed ID: 945997
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Measles antibody titers in multiple sclerosis patients, siblings, and controls.
    Henson TE; Brody JA; Sever JL; Dyken ML; Cannon J
    JAMA; 1970 Mar; 211(12):1985-8. PubMed ID: 5467156
    [No Abstract]   [Full Text] [Related]  

  • 58. Measles vaccine: immunity, reinfection and revaccination.
    Linnemann CC
    Am J Epidemiol; 1973 Jun; 97(6):365-71. PubMed ID: 4713932
    [No Abstract]   [Full Text] [Related]  

  • 59. Persistence of immunity following monovalent and combined live measles, mumps, and rubella virus vaccines.
    Weibel RE; Buynak EB; Stokes J; Hilleman MR
    Pediatrics; 1973 Mar; 51(3):467-75. PubMed ID: 4707864
    [No Abstract]   [Full Text] [Related]  

  • 60. [Development of measles vaccination in Austria].
    Huber EG; Rannon L
    Padiatr Padol; 1973; 8(3):247-56. PubMed ID: 4715034
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.